Alnara Pharmaceuticals, Inc., a medicinal company third world nation non-systemic, orally-delivered protein therapeutics for the therapy of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In if with the MPM investment, managing chief Ashley Dombkowski, Ph.D., will join Alnara’s board of directors.

More: - The rest...